BURNABY, British Columbia, March 12, 2021 (GLOBE NEWSWIRE) — Xenon Prescription drugs Inc. (Nasdaq:XENE), a medical stage biopharmaceutical firm, as we speak introduced the closing of its beforehand introduced underwritten public providing of 5,135,135 frequent shares, which incorporates 810,810 shares bought upon the total train of the underwriters’ choice to buy further shares, and pre-funded warrants to buy 1,081,081 frequent shares. The frequent shares have been provided at a public providing worth of $18.50 per frequent share and the pre-funded warrants have been provided at a worth of $18.4999 per pre-funded warrant, with every pre-funded warrant having an train worth of $0.0001. The mixture gross proceeds to Xenon from the providing, earlier than deducting underwriting reductions and commissions and different providing bills payable by Xenon, have been roughly $115.0 million.
Jefferies, Stifel, and William Blair acted as joint book-running managers for the providing. Needham & Firm and Wedbush PacGrow acted as co-managers for the providing.
A shelf registration assertion regarding the frequent shares provided within the public providing described above was filed with the Securities and Trade Fee (SEC) on June 3, 2020 and declared efficient by the SEC on June 12, 2020. The providing was made solely by the use of a written prospectus and prospectus complement that kind part of the registration assertion. A last prospectus complement and accompanying prospectus regarding the providing was filed with the SEC on March 10, 2021 and can be found on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus might also be obtained by contacting Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, 2nd Ground, New York, NY 10022, or by electronic mail at Prospectus_Department@Jefferies.com, or by cellphone at (877) 821-7388; from Stifel, Nicolaus & Firm, Integrated, One Montgomery Road, Suite 3700, San Francisco, California 94104, Attn: Syndicate, or by cellphone at (415) 364-2720 or by electronic mail at email@example.com; or from William Blair & Firm, L.L.C., Consideration: Prospectus Division, 150 North Riverside Plaza, Chicago, IL 60606, phone: 1-800-621-0687, or by electronic mail: firstname.lastname@example.org.
No securities have been provided or bought, immediately or not directly, in Canada or to any resident of Canada.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase the securities being provided, nor shall there be any sale of the securities being provided in any state or different jurisdiction by which such supply, solicitation or sale can be illegal previous to the registration or qualification underneath the securities legal guidelines of any such state or different jurisdiction.
Xenon Investor/Media Contact:
Xenon Prescription drugs Inc.
Electronic mail: email@example.com